Second-line chemo plus TAS-102 combo for advanced colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests adding a new drug combo (TAS-102 and bevacizumab) to standard second-line treatment for advanced colorectal cancer, followed by local treatments. It may help if your first treatment stopped working and you are otherwise in good health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have colorectal cancer that has spread and cannot be removed by surgery.
- Your first chemotherapy treatment didn't work, and you are about to start your second treatment.
- You must have at least one tumor that can be measured on scans.
- Your overall health and daily activities are good (ECOG score of 0 or 1).
- You have not taken TAS-102 before, and you do not have a bleeding disorder or take full-dose blood thinners.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (liposomal irinotecan, 5-FU/LV, and bevacizumab) for people with advanced colorectal cancer that cannot be removed by surgery. The goal is to see if this treatment is safe and effective in shrinking tumors and improving outcomes.
This trial tests a combination of two drugs, TAS-102 and bevacizumab, as a follow-up maintenance treatment for people with advanced colorectal cancer. The goal is to see if this treatment can keep the cancer from growing after initial chemotherapy and bevacizumab therapy.
This trial is for people with advanced colorectal cancer who are unable to receive standard combination chemotherapy. It tests a combination of two drugs, TAS-102 and bevacizumab, as the first treatment for their condition. The goal is to see if this combination can help slow the growth of the cancer and improve quality of life.
This trial tests a lower dose of a chemotherapy pill (trifluridine/tipiracil) combined with bevacizumab for advanced colorectal cancer that has not responded to at least two prior treatments. The goal is to see if this combination can help control the cancer with fewer side effects.
This trial tests whether adding a drug called bevacizumab (which helps stop blood vessel growth to tumors) to a combination of two chemotherapy drugs (oxaliplatin and TAS-102) can help people with advanced colorectal cancer. It is for people who have not yet received treatment for their advanced cancer.
This Phase 2 trial tests a chemotherapy combination (liposomal irinotecan), along with TAS-102 and bevacizumab, in people with metastatic colon cancer. It may help if your tumor has mismatch repair–proficient features and you’ve already tried standard colon cancer drugs.
Hear when a new Metastatic Colorectal Cancer (CRC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.